Welcome to our dedicated page for Meiragtx Holdings news (Ticker: MGTX), a resource for investors and traders seeking the latest updates and insights on Meiragtx Holdings stock.
MeiraGTx Holdings plc develops clinical-stage genetic medicines for diseases with high unmet need, with recurring updates centered on AAV gene therapy programs, ocular disease, radiation-induced xerostomia, and regulated gene-expression technology. Company news includes clinical disclosures for AAV-hAQP1 and AAV2-hAQP1 in grade 2/3 radiation-induced xerostomia, ophthalmology programs such as AAV-AIPL1 for Leber congenital amaurosis 4, and the acquired bota-vec program for X-linked retinitis pigmentosa.
Updates also cover strategic collaborations and license agreements, in-house manufacturing capabilities for genetic medicines, riboswitch platform development, operating results, financing arrangements, shareholder voting matters, and capital-structure disclosures tied to MGTX ordinary shares.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
MeiraGTx Holdings plc (Nasdaq: MGTX) announced two abstract presentations at the ARVO 2023 Annual Meeting. The first presentation covers the humoral immune response data from the Phase 1/2 MGT009 trial of botaretigene sparoparvovec (bota-vec), aimed at treating X-linked retinitis pigmentosa (XLRP) caused by RPGR gene mutations. This therapy is being developed in partnership with Janssen Pharmaceuticals.
The second focus is on AI-assisted engineered promoters to enhance gene expression in rod photoreceptors. Alexandria Forbes, Ph.D., highlighted the importance of these findings for advancing treatment options for XLRP, which currently has no approved therapies. The presentations will take place on April 23 and 27, 2023, at specific sessions.
MeiraGTx Holdings plc (NASDAQ:MGTX) announced that its CEO, Alexandria Forbes, Ph.D., will participate in several upcoming investor conferences. Key events include:
- Chardan's 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit - April 24, 2023, at 2:30 p.m. ET
- Panel Discussion: Gene Therapy: Positioning for CMC Success - April 25, 2023, at 12:00 p.m. ET
- BofA Securities 2023 Healthcare Conference - May 10, 2023, at 2:35 p.m. PT
- RBC Capital Markets 2023 Global Healthcare Conference - May 17, 2023, at 10:00 a.m. ET
Live webcasts will be accessible on MeiraGTx's Investors page, with replays available for 30 days post-event. MeiraGTx is focused on gene therapy for ocular and neurodegenerative diseases.